536565
TRIMURTHI
Start SIP
Invest Now
Start SIP in TRIMURTHI
Performance
- Low
- ₹61
- High
- ₹66
- 52 Week Low
- ₹25
- 52 Week High
- ₹70
- Open Price₹65
- Previous Close₹62
- Volume2,039
- 50 DMA₹58.77
- 100 DMA₹54.57
- 200 DMA₹45.96
Investment Returns
- Over 1 Month + 19.12%
- Over 3 Month + 3.94%
- Over 6 Month + 58.65%
- Over 1 Year + 148.52%
Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!
Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 60.7
- PEG Ratio
- 0.1
- Market Cap Cr
- 111
- P/B Ratio
- 3.9
- Average True Range
- 3.68
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 1.12
- RSI
- 59.04
- MFI
- 57.66
Novelix Pharmaceuticals Financials
Novelix Pharmaceuticals Technicals
EMA & SMA
Current Price
₹63.00
+
0.55
(0.88%)
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹60.83
- 50 Day
- ₹58.77
- 100 Day
- ₹54.57
- 200 Day
- ₹45.96
Resistance and Support
63.33
- R3 70.67
- R2 68.33
- R1 65.67
- S1 60.67
- S2 58.33
- S3 55.67
Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-12 | Quarterly Results | |
| 2025-11-13 | Quarterly Results | |
| 2025-08-14 | Quarterly Results & A.G.M. | |
| 2025-06-24 | Others | Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company. |
| 2025-05-27 | Audited Results |
Novelix Pharmaceuticals F&O
About Novelix Pharmaceuticals
- NSE Symbol
- TRIMURTHI
- BSE Symbol
- 536565
- ISIN
- INE314I01036
Similar Stocks to Novelix Pharmaceuticals
Novelix Pharmaceuticals FAQs
Novelix Pharmaceuticals share price is ₹63 As on 17 February, 2026 | 00:45
The Market Cap of Novelix Pharmaceuticals is ₹111 Cr As on 17 February, 2026 | 00:45
The P/E ratio of Novelix Pharmaceuticals is 60.7 As on 17 February, 2026 | 00:45
The PB ratio of Novelix Pharmaceuticals is 3.9 As on 17 February, 2026 | 00:45
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.